compound semaglutide for weight loss GLP-1 Loss- Compounded – Lolachi Institute Troubling Findings in Study of

The FDA includes all the GLP-1s from above in the same medicine classification and is evaluating reports of suicidal thoughts or actions in people taking GLP-1s

Key Takeaways Tirzepatide shows the biggest weight loss numbers in most studies

The FDA approved semaglutide for weight loss in June 2021

Anxiety on tirzepatide and muscle pain with tirzepatide have also been reported, though these are less common

Finally, the researchers point out that the profile of people who are using GLP-1 medications to lose weight will continue to evolve as their effectiveness becomes better understood, and we have no way to predict how the larger pattern of food consumption in the United States will evolve with that profile

This allows patients to receive comprehensive information about the effectiveness of these medications, as well as advice about possible side effects